Zacks Investment Research
28 Sept 2026, 16:46 UTC · 1h ago
Verdict
Headline takes no side. We score MIRM +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 2 new · 2 priced in
Mirum Pharmaceuticals announced FDA approval of Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older.
Newannounced September 28, 2026
So whatCommercial availability starting in October provides a concrete catalyst for revenue generation in Q4 2026.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
In the phase II PROGRESS study, Atebrioz patients saw an average 3.2 cubic-centimeter reduction in new HO lesion volume versus a 24.6 cubic-centimeter increase in the placebo group after 24 weeks.
Newannounced September 28, 2026
So whatThe delta of 27.8 cubic-centimeters between treatment and placebo supports the efficacy profile required for high orphan drug pricing.
More positive than 87% of claims this week
FOP is an ultra-rare genetic disease affecting approximately 300 people in the US and 900 worldwide.
Priced inbackground medical data
So whatThe total addressable market (TAM) is limited to 1,200 patients globally, capping the absolute peak sales potential.
More positive than 66% of claims this week
Mirum Pharmaceuticals obtained exclusive worldwide rights to Atebrioz from Incyte in April 2026.
Priced inoccurred in April 2026
So whatIncyte's eligibility for tiered royalties on net sales will act as a permanent margin drag on MIRM's top line.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company received FDA approval for its drug Atebrioz for the treatment of FOP.
More positive than 71% of ticker scores this week
The company is eligible for milestone payments and royalties following the FDA approval of a drug it developed and licensed to Mirum.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2h ago
−3.0%
Price is moving against the score
$87.00 vs $89.70 close before publication (Sep 25) · not market-adjusted
MIRM chart →
